NCT02370160View on ClinicalTrials.gov

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 21, 2015

Primary Completion Date

April 8, 2018

Study Completion Date

April 8, 2018

Conditions
Refractory B-Lineage LeukemiaRelapsed B-Lineage LeukemiaRefractory B-Lineage LymphomaRelapsed B-Lineage Lymphoma
Interventions
BIOLOGICAL

DT2219ARL

DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02370160 - HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter